Avila Therapeutics
Waltham
About Avila Therapeutics
Avila Therapeutics designs and develops covalent drugs for viral infections, cancers, and autoimmune diseases. It offers AVL-181, a small molecule hepatitis C virus protease inhibitor. Avila Therapeutics has a strategic alliance with Sanofi-Aventis. The company was incorporated in 2006 and is based in Waltham, Massachusetts. As of March 7, 2012, Avila Therapeutics operates as a subsidiary of Celgene Corporation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $59.3M
- Funding stage: M&A
- Last round: Series Unknown (Dec 2020)
- Website: avilatx.com
- Phone: 781-891-0086
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/avila-therapeutics-62853 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.